Cell membrane coated nanoparticles: next-generation therapeutics

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Fang RH, Jiang Y, Fang JC, Zhang L. Cell membrane-derived nanomaterials for biomedical applications. Biomaterials 128, 69–83 (2017). •• This paper has shown the therapeutic benefits of using cell membrane coated nanoparticles and their effect on a molecular scale.
  Medline CASGoogle Scholar
• 2 Surendiran A, Sandhiya S, Pradhan S, Adithan C. Novel applications of nanotechnology in medicine. Indian J. Med. Res. 130(6), 689–701 (2009).
  Medline CASGoogle Scholar
• 3 Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: size matters. J. Nanobiotechnol. 12(1), 5 (2014).
  MedlineGoogle Scholar
• 4 Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm. Sin. B 5(5), 442–453 (2015).
  MedlineGoogle Scholar
• 5 Fahs S, Patil-Sen Y, Snape TJ. Foldamers as anticancer therapeutics: targeting protein-protein interactions and the cell membrane. ChemBioChem 16(13), 1840–1853 (2015).
  Medline CASGoogle Scholar
• 6 Fahs S, Rowther FB, Dennison SR, Patil-Sen Y, Warr T, Snape TJ. Development of a novel, multifunctional, membrane-interactive pyridinium salt with potent anticancer activity. Bioorg. Med. Chem. Lett. 24(15), 3430–3433 (2014).
  Medline CASGoogle Scholar
• 7 Patil-Sen Y, Dennison SR, Snape TJ. Functional foldamers that target bacterial membranes: the effect of charge, amphiphilicity and conformation. Biorg. Med. Chem. 24(18), 4241–4245 (2016).
  Medline CASGoogle Scholar
• 8 Fang RH, Hu C-MJ, Chen KNH et al. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 5(19), 8884–8888 (2013).
  Medline CASGoogle Scholar
• 9 Bose RJC, Arai Y, Ahn JC, Park H, Lee S-H. Influence of cationic lipid concentration on properties of lipid–polymer hybrid nanospheres for gene delivery. Int. J. Nanomed. 10, 5367–5382 (2015).
  Medline CASGoogle Scholar
• 10 Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 48(3), 416–427 (2013).
  Medline CASGoogle Scholar
• 11 Mout R, Moyano DF, Rana S, Rotello VM. Surface functionalization of nanoparticles for nanomedicine. Chem. Soc. Rev. 41(7), 2539–2544 (2012).
  Medline CASGoogle Scholar
• 12 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751–760 (2007).
  Medline CASGoogle Scholar
• 13 Hofheinz R-D, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs 16(7), 691–707 (2005).
  Medline CASGoogle Scholar
• 14 Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1(3), 297–315 (2006).
  CASGoogle Scholar
• 15 Kulkarni CV, Moinuddin Z, Patil-Sen Y, Littlefield R, Hood M. Lipid-hydrogel films for sustained drug release. Int. J. Pharm. 479(2), 416–421 (2015).
  Medline CASGoogle Scholar
• 16 Hans M, Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 6(4), 319–327 (2002).
  CASGoogle Scholar
• 17 Enlow EM, Luft JC, Napier ME, Desimone JM. Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings. Nano Lett. 11(2), 808–813 (2011).
  Medline CASGoogle Scholar
• 18 Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev. 41(7), 2590–2605 (2012).
  Medline CASGoogle Scholar
• 19 Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995–4021 (2005).
  Medline CASGoogle Scholar
• 20 Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem. Soc. Rev. 41(6), 2256–2282 (2012).
  Medline CASGoogle Scholar
• 21 Patil-Sen Y, Tiddy GJT, Brezesinski G, Dewolf C. A monolayer phase behaviour study of phosphatidylinositol, phosphatidylinositol 4-monophosphate and their binary mixtures with distearoylphosphatidylethanolamine. PCCP 6(7), 1562–1565 (2004).
  CASGoogle Scholar
• 22 Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154(2), 123–140 (1997).
  CASGoogle Scholar
• 23 Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther. 1(6), 923–947 (2001).
  Medline CASGoogle Scholar
• 24 Ekimov A, Onushchenko A. Quantum size effect in three-dimensional microscopic semiconductor crystals. Pis'ma Zh. Eksp. Teor. Fiz. 34, 363–366 (1981).
  Google Scholar
• 25 Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R, Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat. Methods 5(9), 763–775 (2008).
  Medline CASGoogle Scholar
• 26 Sinha N, Yeow JT. Carbon nanotubes for biomedical applications. IEEE Trans. NanoBioscience 4(2), 180–195 (2005).
  MedlineGoogle Scholar
• 27 Gaunt NP, Patil-Sen Y, Baker MJ, Kulkarni CV. Carbon nanotubes for stabilization of nanostructured lipid particles. Nanoscale 7(3), 1090–1095 (2015).
  Medline CASGoogle Scholar
• 28 Patil-Sen Y, Sadeghpour A, Rappolt M, Kulkarni CV. Facile preparation of internally self-assembled lipid particles stabilized by carbon nanotubes. J. Vis. Exp. (108), 53489 (2016).
  MedlineGoogle Scholar
• 29 Kulkarni M, Patil-Sen Y, Junkar I, Kulkarni CV, Lorenzetti M, Iglic A. Wettability studies of topologically distinct titanium surfaces. Colloid Surf. B 129, 47–53 (2015).
  Medline CASGoogle Scholar
• 30 Naskar J, Roy S, Joardar A, Das S, Banerjee A. Self-assembling dipeptide-based nontoxic vesicles as carriers for drugs and other biologically important molecules. Org. Biomol. Chem. 9(19), 6610–6615 (2011).
  Medline CASGoogle Scholar
• 31 Bawa R, Fung S-Y, Shiozaki A et al. Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis. Nanomed. Nanotechnol. Biol. Med. 8(5), 647–654 (2012).
  CASGoogle Scholar
• 32 Majid A, Patil-Sen Y, Ahmed W, Sen T. Tunable self-assembled peptide structure: a novel approach to design dual-use biological agents. Materials Today 4(1), 32–40 (2017).
  Google Scholar
• 33 Crist RM, Grossman JH, Patri AK et al. Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr. Biol. (Camb). 5(1), 66–73 (2013).
  Medline CASGoogle Scholar
• 34 Shvedova AA, Kagan VE, Fadeel B. Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. Annu. Rev. Pharmacol. Toxicol. 50, 63–88 (2010).
  Medline CASGoogle Scholar
• 35 Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761–769 (2008). •• Pioneers in the field of nanomedicine. Zhang L has pioneered the development of cell membrane coated nanoparticles. This paper is of significant interest as it outlines drug delivery systems used in 2008, its benefits and drawbacks with respect to their applications.
  Medline CASGoogle Scholar
• 36 Fox ME, Szoka FC, Fréchet JMJ. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc. Chem. Res. 42(8), 1141–1151 (2009).
  Medline CASGoogle Scholar
• 37 Barenholz YC. Doxil^® – the first FDA-approved nano-drug: lessons learned. J. Control. Release 160(2), 117–134 (2012).
  Medline CASGoogle Scholar
• 38 Dawidczyk CM, Kim C, Park JH et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control. Release 187, 133–144 (2014).
  Medline CASGoogle Scholar
• 39 Maier-Hauff K, Ulrich F, Nestler D et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103(2), 317–324 (2011).
  MedlineGoogle Scholar
• 40 He H, Pham-Huy LA, Dramou P, Xiao D, Zuo P, Pham-Huy C. Carbon nanotubes: applications in pharmacy and medicine. Biomed Res. Int. 2013, 578290, 1–12 (2013).
  Google Scholar
• 41 Gao Z, Fain HD, Rapoport N. Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol. Pharm. 1(4), 317–330 (2004).
  Medline CASGoogle Scholar
• 42 Zhang H. Erythrocytes in nanomedicine: an optimal blend of natural and synthetic materials. Biomater. Sci. 4(7), 1024–1031 (2016).
  Medline CASGoogle Scholar
• 43 Gupta N, Patel B, Ahsan F. Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization. Pharm. Res. 31(6), 1553–1565 (2014).
  Medline CASGoogle Scholar
• 44 Hu C-MJ, Fang RH, Copp J, Luk BT, Zhang L. A biomimetic nanosponge that absorbs pore-forming toxins. Nat. Nano 8(5), 336–340 (2013). • This was the first paper to show that erythrocyte membranes could be used as targets to adsorb pore-forming toxins rather than a drug delivery system.
  Medline CASGoogle Scholar
• 45 Hwang J, Jeong Y, Park JM, Lee KH, Hong JW, Choi J. Biomimetics: forecasting the future of science, engineering, and medicine. Int. J. Nanomed. 10, 5701–5713 (2015).
  Medline CASGoogle Scholar
• 46 Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 12(8), 991–998 (2007).
  Medline CASGoogle Scholar
• 47 Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 27(12), 2569–2589 (2010).
  Medline CASGoogle Scholar
• 48 Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging Med. Surg. 1(1), 35–40 (2011).
  MedlineGoogle Scholar
• 49 Fang M, Peng C-W, Pang D-W, Li Y. Quantum dots for cancer research: current status, remaining issues, and future perspectives. Cancer Biol. Med. 9(3), 151–163 (2012).
  Medline CASGoogle Scholar
• 50 Alibolandi M, Abnous K, Sadeghi F, Hosseinkhani H, Ramezani M, Hadizadeh F. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: in vitro and in vivo evaluation. Int. J. Pharm. 500(1–2), 162–178 (2016).
  Medline CASGoogle Scholar
• 51 Parodi A, Quattrocchi N, Van De Ven AL et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8(1), 61–68 (2013).
  Medline CASGoogle Scholar
• 52 Antonelli A, Sfara C, Manuali E, Bruce IJ, Magnani M. Encapsulation of superparamagnetic nanoparticles into red blood cells as new carriers of MRI contrast agents. Nanomedicine 6(2), 211–223 (2011). • Pioneers in the field of erythrocyte drug carriers (nanoerythrosomes). This paper has shown tremendous diagnostic potential of nanoerythrosomes for MRI imaging.
  CASGoogle Scholar
• 53 Wei X, Gao J, Fang RH et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials 111, 116–123 (2016).
  Medline CASGoogle Scholar
• 54 Fang RH, Hu CMJ, Luk BT et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 14(4), 2181–2188 (2014).
  Medline CASGoogle Scholar
• 55 Gao WW, Fang RH, Thamphiwatana S et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett. 15(2), 1403–1409 (2015).
  Medline CASGoogle Scholar
• 56 Lai PY, Huang RY, Lin SY, Lin YH, Chang CW. Biomimetic stem cell membrane-camouflaged iron oxide nanoparticles for theranostic applications. RSC Adv. 5(119), 98222–98230 (2015).
  CASGoogle Scholar
• 57 Hu CMJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang LF. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108(27), 10980–10985 (2011).
  Medline CASGoogle Scholar
• 58 Hu CMJ, Fang RH, Luk BT et al. ‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 5(7), 2664–2668 (2013).
  Medline CASGoogle Scholar
• 59 Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339(6122), 971–975 (2013).
  Medline CASGoogle Scholar
• 60 Gao WW, Hu CMJ, Fang RH, Luk BT, Su J, Zhang LF. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv. Mater. 25(26), 3549–3553 (2013).
  Medline CASGoogle Scholar
• 61 Rao L, Bu LL, Xu JH et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small 11(46), 6225–6236 (2015).
  Medline CASGoogle Scholar
• 62 Li LL, Xu JH, Qi GB, Zhao XZ, Yu FQ, Wang H. Core-shell supramolecular gelatin nanoparticles for adaptive and “on-demand” antibiotic delivery. ACS Nano 8(5), 4975–4983 (2014).
  Medline CASGoogle Scholar
• 63 Piao JG, Wang LM, Gao F, You YZ, Xiong YJ, Yang LH. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 8(10), 10414–10425 (2014).
  Medline CASGoogle Scholar
• 64 Rao L, Xu JH, Cai B et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology 27(8), 085106 (2016).
  MedlineGoogle Scholar
• 65 Wang ZJ, Li J, Cho J, Malik AB. Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nat. Nanotechnol. 9(3), 204–210 (2014).
  Medline CASGoogle Scholar
• 66 Baggiolini M. Chemokines and leukocyte traffic. Nature 392(6676), 565–568 (1998).
  Medline CASGoogle Scholar
• 67 Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration – the multistep paradigm. Cell 76(2), 301–314 (1994).
  Medline CASGoogle Scholar
• 68 Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv. Healthc. Mater. 4(11), 1645–1652 (2015).
  Medline CASGoogle Scholar
• 69 Gao C, Wu Z, Lin Z, Lin X, He Q. Polymeric capsule-cushioned leukocyte cell membrane vesicles as a biomimetic delivery platform. Nanoscale 8(6), 3548–3554 (2016).
  Medline CASGoogle Scholar
• 70 Xuan MJ, Shao JX, Dai LR, Li JB, He Q. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl. Mater. Interfaces 8(15), 9610–9618 (2016).
  Medline CASGoogle Scholar
• 71 Krishnamurthy S, Gnanasammandhan MK, Xie C, Huang K, Cui MY, Chan JM. Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. Nanoscale 8(13), 6981–6985 (2016).
  Medline CASGoogle Scholar
• 72 Osta WA, Chen Y, Mikhitarian K et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64(16), 5818–5824 (2004).
  Medline CASGoogle Scholar
• 73 Zhu JY, Zheng DW, Zhang MK et al. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett. 16(9), 5895–5901 (2016). • This paper is of considerable interest as it shows that functionalization with cancer cell membrane allows specific cancer cell targeting and internalization.
  Medline CASGoogle Scholar
• 74 Sun HP, Su JH, Meng QS et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv. Mater. 28(43), 9581–9588 (2016).
  Medline CASGoogle Scholar
• 75 Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8(9), 726–736 (2008).
  Medline CASGoogle Scholar
• 76 Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 10(2), 228–241 (2003).
  Medline CASGoogle Scholar
• 77 De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr. Mol. Med. 12(5), 574–591 (2012).
  Medline CASGoogle Scholar
• 78 Gao CY, Lin ZH, Jurado-Sanchez B, Lin XK, Wu ZG, He Q. Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small 12(30), 4056–4062 (2016).
  Medline CASGoogle Scholar
• 79 George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol. 28(5 Suppl. 17), 27–33 (2001).
  Medline CASGoogle Scholar
• 80 Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 3(1), 16–20 (2009).
  Medline CASGoogle Scholar
• 81 Hu CMJ, Fang RH, Wang KC et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526(7571), 118–121 (2015).
  Medline CASGoogle Scholar
• 82 Hu QY, Sun WJ, Qian CG, Wang C, Bomba HN, Gu Z. Anticancer platelet-mimicking nanovehicles. Adv. Mater. 27(44), 7043–7050 (2015). • This paper is of interest as it shows the anticancer effect of coating nanoparticle cores with platelet membranes.
  Medline CASGoogle Scholar
• 83 Acevedo R, Fernandez S, Zayas C et al. Bacterial outer membrane vesicles and vaccine applications. Front. Immunol. 5, 121–126 (2014).
  MedlineGoogle Scholar
• 84 Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The bacterial ghost platform system: production and applications. Bioeng. Bugs 1(5), 326–336 (2010).
  MedlineGoogle Scholar
• 85 Dehaini D, Wei X, Fang RH et al. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv. Mater. 29(16), 1606209 (2017).
  Google Scholar
• 86 Rao L, Meng QF, Bu LL et al. Erythrocyte membrane-coated upconversion nanoparticles with minimal protein adsorption for enhanced tumor imaging. ACS Appl. Mater. Interfaces 9(3), 2159–2168 (2017).
  Medline CASGoogle Scholar
• 87 Luk BT, Fang RH, Hu C-MJ et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics 6(7), 1004–1011 (2016).
  Medline CASGoogle Scholar
• 88 Palomba R, Parodi A, Evangelopoulos M et al. Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability. Sci. Rep. 6, 1–11 (2016).
  MedlineGoogle Scholar
• 89 Chhabria V, Beeton S. Development of nanosponges from erythrocyte ghosts for removal of streptolysin-O from mammalian blood. Nanomedicine 11(21), 2797–2807 (2016).
  CASGoogle Scholar
• 90 Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. In: Annual Review of Biomedical Engineering, Vol. 14. Yarmush ML (Ed.). Institute of Biomaterials and Biomedical Engineering; Terrence Donnelly Center for Cellular and Biomolecular Research; Materials Science and Engineering; Chemical Engineering; and Chemistry, University of Toronto, Toronto, ON, Canada, 1–16 (2012).
  Google Scholar
• 91 Luk BT, Jack Hu C-M, Fang RH et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 6(5), 2730–2737 (2014).
  Medline CASGoogle Scholar
• 92 Meyer RA, Sunshine JC, Green JJ. Biomimetic particles as therapeutics. Trends Biotechnol. 33(9), 514–524 (2015).
  Medline CASGoogle Scholar
• 93 Zhang L, Li R, Chen H et al. Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. Int. J. Nanomed. 12, 2129 (2017).
  Medline CASGoogle Scholar
• 94 Rao L, Bu LL, Cai B et al. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv. Mater. 28(18), 3460–3466 (2016).
  Medline CASGoogle Scholar
• 95 Chen Z, Zhao PF, Luo ZY et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano 10(11), 10049–10057 (2016).
  Medline CASGoogle Scholar
• 96 Gao WW, Hu CMJ, Fang RH, Zhang LF. Liposome-like nanostructures for drug delivery. J. Mater. Chem. B 1(48), 6569–6585 (2013).
  CASGoogle Scholar
• 97 He WP, Frueh J, Wu ZW, He Q. How leucocyte cell membrane modified janus microcapsules are phagocytosed by cancer cells. ACS Appl. Mater. Interfaces 8(7), 4407–4415 (2016).
  Medline CASGoogle Scholar
• 98 Rao L, He Z, Meng QF et al. Effective cancer targeting and imaging using macrophage membrane-camouflaged upconversion nanoparticles. J. Biomed. Mater. Res. A 105(2), 521–530 (2017).
  Medline CASGoogle Scholar
• 99 Evangelopoulos M, Parodi A, Martinez JO et al. Cell source determines the immunological impact of biomimetic nanoparticles. Biomaterials 82, 168–177 (2016).
  Medline CASGoogle Scholar
• 100 Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his nobel prize. Pharmacology 82(3), 171–179 (2008).
  Medline CASGoogle Scholar
• 101 Luk BT, Zhang LF. Cell membrane-camouflaged nanoparticles for drug delivery. J. Control. Release 220, 600–607 (2015).
  Medline CASGoogle Scholar
• 102 Tan SW, Wu TT, Zhang D, Zhang ZP. Cell or cell membrane-based drug delivery systems. Theranostics 5(8), 863–881 (2015).
  Medline CASGoogle Scholar
• 103 Anselmo AC, Modery-Pawlowski CL, Menegatti S et al. Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano 8(11), 11243–11253 (2014).
  Medline CASGoogle Scholar